Sai Life Sciences Stock Rallies 9% to Record High After Q2 Results

Sai Life’s Q2 Growth Puts Its Expansion Plans in Focus

Strong revenue and profit growth lifted the shares, while a large investment programme and a slight margin dip remain important parts of the story.

Revenue growth outpaced profit growth

Consolidated revenue rose 23% year on year to ₹659 crore in Q2FY27, from ₹537 crore a year earlier. Net profit increased 17% to ₹98 crore, compared with ₹84 crore. EBITDA grew 20% to ₹187 crore from ₹156 crore, indicating that operating earnings also advanced alongside sales.

The difference between revenue and profit growth rates is worth watching, rather than treating the headline expansion as the whole picture. EBITDA margin eased to 28% from 29% in the year-ago quarter. That means the company converted a slightly smaller share of revenue into EBITDA, even as the absolute amount increased. The figures do not by themselves establish why the margin declined, but future results will show whether it stabilises as the business grows.

New client engagements could broaden the growth base

Sai Life said it has started operations with its first end-to-end integrated collaboration, which it onboarded in the previous quarter. The engagement is expected to become fully functional in the third quarter. It also converted another large pharmaceutical relationship into a similar strategic engagement and said discussions are under way with a few companies to expand its integrated outsourcing model.

These developments matter because they move the company’s stated strategy beyond attracting individual projects towards deeper, integrated client relationships. If those engagements become operational and develop as expected, they could support the business’s longer-term growth visibility. However, the company has not provided revenue contributions from the new collaborations in the information available here, so their eventual scale and timing remain uncertain.

Capital spending raises the execution stakes

Capital expenditure reached ₹621 crore in the first six months of FY27, including ₹358 crore in Q2. Sai Life remains on track for its overall capex projection of ₹1,100 crore to ₹1,300 crore. The investment programme signals that capacity expansion is central to its plans, but the returns will depend on how effectively the company brings that capacity into use and builds business around it.

SBI Securities attributed the stock’s re-rating to execution across the CRO and CDMO businesses, earnings delivery, capacity investment and deeper engagement with innovator pharma clients. That is the brokerage’s assessment, not a guarantee of future performance. For investors, the operational progress of the new collaboration and the relationship between expansion spending, growth and margins will be important measures of delivery.

A record high brings expectations into view

Sai Life shares rose nearly 9% intraday to a record ₹1,897.30 after opening marginally lower at ₹1,738.80. They later pared some gains and were up 4.7% at ₹1,825.90 as of 11 a.m. Around 6.5 million shares, worth ₹1,197.23 crore, changed hands, making the stock one of the exchange’s most actively traded by value.

The move followed a sharp run-up: the stock had gained 105% so far in 2026, while the Nifty 50 had declined 5%, and Sai Life was up 112% over the past year. This context makes the latest results relevant not only for their growth, but also for the expectations investors may already have built into the shares. A strong quarter can support sentiment, but it does not remove the need to assess valuation, execution and margin trends.

Key Highlights

• Q2FY27 revenue increased 23% year on year to ₹659 crore.
• Net profit rose 17% to ₹98 crore; EBITDA advanced 20% to ₹187 crore.
• EBITDA margin narrowed to 28% from 29% a year earlier.
• First end-to-end integrated collaboration has begun operations and is expected to be fully functional in Q3.
• Six-month capex stood at ₹621 crore against a full-year projection of ₹1,100 crore to ₹1,300 crore.

Investor Note: The quarter showed healthy growth, but investors may want to track margin stability, the ramp-up of integrated client engagements and progress against the capex plan. After a substantial share-price rise, business execution and the price paid for future growth both warrant careful consideration.